Pharma and life sciences insights

InsightsHealthcare and pharma insights

Pharma and life sciences insights

Read our latest pharma and life sciences insights.
24 Jul 2026

The future for UK pharmaceutical & life sciences

UK pharmaceutical and life sciences leaders enter the second half of 2026 with optimism about growth, despite confidence in the wider macroeconomic softening. For a sector where demand holds firm through almost any cycle, the months ahead will be defined by a combination of caution and underlying resilience that is increasingly focused on protecting the R&D pipeline that sustains it.

Read more
22 May 2026

Growing global report - Life Sciences

Life sciences organisations are stepping into a new phase of global growth - expanding into new markets, adapting to shifting demand, and navigating increasing complexity, all while trying to keep innovation moving at pace.

Read more
17 Apr 2026

Cyber security and innovation in life sciences

The life sciences sector stands at a fascinating crossroads. On one hand, these organisations are at the forefront of progress, advancing technology and science with innovations like AI-driven drug discovery and targeted biologics. On the other, it is grappling with an expanding threat landscape that encompasses everything from state-sponsored attacks to supply chain vulnerabilities, just like other...

Read more
Sector-LS.jpg
30 Mar 2026

C-suite 2026: life sciences highlights

Globally, the life sciences and pharmaceutical sector finds itself navigating a climate defined by volatility, hard‑edged economic pressure and relentlessly shifting supply chains. In fact, this is the sector hit the hardest by the majority of external trends impacting businesses and creating barriers to growth – simultaneously. Within this environment, a majority (84%) of sector leaders maintain...

Read more
23 Mar 2026

Accelerating life sciences re-shoring in Europe

In Europe, re-shoring life sciences production became a key strategic goal for governments in the wake of Covid. However, not all of these initiatives have progressed as expected. A major new report from Forvis Mazars suggests new ways to create success stories across the continent.

Read more
An image of medicine in shelves in a pharmacy
9 Jan 2026

The UK-US drug pricing deal

For much of the past year, the UK’s medicines pricing debate has cast a long shadow over the life sciences sector. The deadlock over NHS rebates – and the uncertainty surrounding the successor to VPAG – has created unease among global pharmaceutical companies already navigating an increasingly competitive international landscape.

Read more
6 Oct 2025

Re-shoring life sciences for a sustainable future

The pandemic, geopolitical tensions and the climate emergency have revealed the vulnerabilities of Europe’s life sciences industry. Relocating pharmaceutical and medtech production is no longer a choice but a strategic necessity to safeguard sovereignty, strengthen competitiveness and ensure long-term sustainability.

Read more
Young woman networking with social media on smartphone in city street at night. Defocus street lights in background. Close up of woman checking social media on smartphone in the city. People engaging in networking with technology. Lifestyle and technology
6 Jun 2025

The potential of AI in pharma

As with many industries, the pharmaceutical and life sciences sector is embracing artificial intelligence (AI) to drive transformation. The sector is using the technology to reshape drug development, improve organisational processes, support R&D and more.

Read more
Business people negotiating at boardroom behind closed doors - consulting - diversity - Meeting Office Business Teamwork Working Advice Board Room Occupation Discussion Corporate Business People Cooperation Leadership Organised Group Marketing Manager Partnership
21 Mar 2025

You only get one ‘Day One’

The UK pharmaceutical and life sciences sector is braced for a busier year in terms of mergers and acquisitions (M&A), following a quiet 2024, both in terms of deal volume and value.

Read more
An image of a female scientist in a laboratory
17 Jan 2025

Top trends for the pharma & life sciences sector

As we move into 2025, we assess the key industry trends that are set to define the year ahead. Our experts explore how businesses in the pharma and life sciences sector can effectively adapt to emerging opportunities and address the challenges that lie ahead.

Read more
View from below of skyscrapers construction site, New York City, America. Real estate properties with high rise buildings with clear skies in background.
6 Jan 2025

2025 isn’t forecastable. But we will try

Forecasts are at the heart of investment management. Understanding the world as is, even perfectly, offers little value to investors, as that knowledge is “priced in” by financial markets. Forecasts, putting a price on future events, such as earnings, economic growth, inflation, etc, are where the true value lies.

Read more
6 Dec 2024

What the Budget means for the life sciences sector

As we step into 2025, the effects of the Autumn Budget 2024 will start to take shape, leaving businesses in the pharma and life sciences sector grappling with its implications. Was it a step forward or a setback? Only time will tell as the changes take effect.

Read more
Female scientist pipetting into sample in laboratory
11 Nov 2024

Boehringer Ingelheim's £21 million VAT victory

In a significant decision for the pharmaceutical industry, the UK First Tier Tribunal (FTT) has ruled in favour of Boehringer Ingelheim, allowing the company to reclaim £21 million of overpaid VAT. This ruling is a major development for suppliers of branded medicines to the NHS, offering clarity on how VAT should be treated in relation to rebate payments under the UK’s voluntary price control schemes.

Read more
Image of a woman researcher in a lab looking through a microscope
25 Oct 2024

Is the R&D tax credit regime fit for purpose?

Recent developments suggest that the R&D tax credit regime, established almost 25 years ago to support innovative UK businesses, is facing critical challenges. Although it has played a crucial role in driving value creation in sectors like pharmaceuticals and life sciences, its effectiveness is increasingly questioned.

Read more
21 Aug 2024

Third party risk management

In the last few weeks, we have seen both the ransomware attack on the NHS in the news, and more recently, the impact caused by a software bug in an update from a cyber security firm, causing IT outages across the globe. These two incidents, added to the traditional high risks of issues such as bribery and corruption, stress the importance of third party risk management and due diligence.

Read more
Medicine, Pharmaceutical Industry, Manufacturing, Clean Room, Laboratory, Industry, Hygiene, Pharmaceutical Factory, Factory, Technician, Healthcare And Medicine, Medical Equipment, Production Line, Occupation, Biology, White People, Pharmaceutical Manufacturing Machine, Protective Workwear, Technology, Automated, Protective Glove, Chemical, Clean, Differential Focus, Equipment, Manufacturing Occupation, Protective Face Mask, Reflection, Working, 25-29 Years, Adults Only, Biotechnology, Chemistry, Colour Image, Control Panel, Female Doctor, Glass - Material, Horizontal, Industrial Equipment, Laboratory Equipment, Machine Part, Manufacturing Machinery, Medical Occupation, Medical Research, Medical Supplies, One Person, People, Photography, Place of Work, Professional Occupation, Protection, STEM - Topic, Science, Science and Technology, Serbia, Stainless Steel, Uniform,

Pharma and Life Sciences - Exploring tax reliefs

Pharma and life sciences businesses, understandably, tend to focus on the science and development of ideas and the groundbreaking therapies this might lead to. However, leveraging all available resources, such as allowances and tax reliefs, is also something these companies should be considering. While leading pharmaceutical companies have large departments dedicated to this, smaller businesses in...

Read more
Mazars sponsors FT Live Global Pharma and Biotech Summit - web 2

Mazars sponsors FT Live Global Pharma Summit

Mazars is committed to supporting the pharma and life sciences sector; helping companies to navigate disruption, embrace innovation and grow with confidence. That’s why we recently partnered with FT Live for their Global Pharma and Biotech Summit - bringing the industry together to explore the latest trends, share top expertise and drive growth.

Read more
Chemist and female scientist gesturing while explaining in meeting with protective eyeglasses at laboratory - Biotech. - Laboratory Healthcare And Medicine - Caucasian people Engineer Technology Trainee Women Technician Engineering Working Young Adult People Workshop Only Women Differential Focus

VAT for a healthy supply chain

The pandemic demonstrated beyond any reasonable doubt that the life sciences, pharma and healthcare sectors play a critical role in society. Developing, testing and manufacturing vaccines was key to beating Covid-19.

Read more
What’s next for boards in the UK life sciences industry - Web

Boards in the UK life sciences industry

Life sciences organisations currently have great potential to thrive in the UK however, they are also facing significant challenges which, if not managed correctly, will limit this opportunity. Hear from industry experts to learn what boards must consider to successfully govern in this post-Covid era.

Read more
What the Spring Budget 2023 means for the life sciences sector - Web

Spring Budget 2023 – life sciences sector

Clearly, Jeremy Hunt was wanting to champion the importance of the life sciences sector to the UK’s economy. It was probably singled out more times in his speech than any other sector and a few of the reforms announced today go some way to address criticism around the competitiveness of the UK corporation tax system for this sector, particularly in advance of the rise of the headline rate to 25% from...

Read more
Life sciences M&A update - Web

Life sciences M&A update

Amidst uncertainty in the wider economy, life sciences companies need to be better prepared to de-risk investment decisions and complete transactions. Whilst this may have a short-term impact on M&A activity, we expect deal volumes to recover by the end of the year.

Read more
International RandD in pharma

International R&D tax incentives

Bringing new drugs to market is risky, lengthy, complex, and costly, so pharmaceutical companies are rationalising their major R&D centres worldwide to collaborate with partners. This is where international R&D tax incentives play their part.

Read more

Contact us

+44 20 7063 4000
Meet our local team
Discover our offices
Or use our contact form